Sandra Robrecht

3.8k total citations
45 papers, 496 citations indexed

About

Sandra Robrecht is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Sandra Robrecht has authored 45 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Genetics, 27 papers in Pathology and Forensic Medicine and 23 papers in Immunology. Recurrent topics in Sandra Robrecht's work include Chronic Lymphocytic Leukemia Research (43 papers), Lymphoma Diagnosis and Treatment (27 papers) and Immunodeficiency and Autoimmune Disorders (21 papers). Sandra Robrecht is often cited by papers focused on Chronic Lymphocytic Leukemia Research (43 papers), Lymphoma Diagnosis and Treatment (27 papers) and Immunodeficiency and Autoimmune Disorders (21 papers). Sandra Robrecht collaborates with scholars based in Germany, United States and United Kingdom. Sandra Robrecht's co-authors include Michael Hallek, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Jasmin Bahlo, Matthias Ritgen, Paula Cramer, Julia von Tresckow, Anna‐Maria Fink and Clemens‐Martin Wendtner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Sandra Robrecht

37 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Robrecht Germany	12	415	360	203	98	75	45	496
Panagiotis Baliakas Sweden	11	312 0.8×	224 0.6×	156 0.8×	95 1.0×	60 0.8×	34	443
Tamia Nguyen Australia	7	328 0.8×	204 0.6×	109 0.5×	175 1.8×	77 1.0×	15	465
Fiona Bennett United Kingdom	8	511 1.2×	391 1.1×	316 1.6×	84 0.9×	74 1.0×	12	585
Kimberly J. Stockero United States	9	285 0.7×	223 0.6×	160 0.8×	65 0.7×	39 0.5×	9	390
Sharron Glide United Kingdom	4	522 1.3×	417 1.2×	259 1.3×	53 0.5×	116 1.5×	5	578
Elisa Tammiso Italy	12	332 0.8×	261 0.7×	203 1.0×	67 0.7×	60 0.8×	18	410
Manit Munshi United States	13	543 1.3×	473 1.3×	243 1.2×	179 1.8×	70 0.9×	40	632
Magdalena Piotrowska Poland	4	429 1.0×	400 1.1×	222 1.1×	84 0.9×	101 1.3×	7	536
Ghayathri Jeyakumar United States	4	283 0.7×	253 0.7×	125 0.6×	89 0.9×	106 1.4×	9	388
Carsten Schwänen Germany	6	329 0.8×	325 0.9×	106 0.5×	49 0.5×	187 2.5×	8	497

Countries citing papers authored by Sandra Robrecht

Since Specialization

Citations

This map shows the geographic impact of Sandra Robrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Robrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Robrecht more than expected).

Fields of papers citing papers by Sandra Robrecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Robrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Robrecht. The network helps show where Sandra Robrecht may publish in the future.

Co-authorship network of co-authors of Sandra Robrecht

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Robrecht. A scholar is included among the top collaborators of Sandra Robrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Robrecht. Sandra Robrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goede, Valentin, Kirsten Fischer, Sandra Robrecht, et al.. (2025). Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia. Blood Advances. 9(10). 2431–2435. 1 indexed citations

Mellinghoff, Sibylle C., Sandra Robrecht, Rosanne Sprute, et al.. (2024). Hybrid immunity to SARS‐CoV ‐2 in patients with chronic lymphocytic leukemia. European Journal Of Haematology. 112(5). 788–793.

Tresckow, Julia von, Sandra Robrecht, Anna‐Maria Fink, et al.. (2024). CLL-465 Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG). Clinical Lymphoma Myeloma & Leukemia. 24. S354–S355.

Riecke, Armin, Eugen Tausch, Deyan Y. Yosifov, et al.. (2023). Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial. Blood. 142(Supplement 1). 199–199.

Tresckow, Julia von, Sandra Robrecht, Ali Aldaoud, et al.. (2023). Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group. Annals of Hematology. 102(11). 3083–3090. 4 indexed citations

Kutsch, Nadine, Rudy Ligtvoet, Sandra Robrecht, et al.. (2023). Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry. Blood. 142(Supplement 1). 4644–4644. 3 indexed citations

Fürstenau, Moritz, Jonathan M. Weiss, Sandra Robrecht, et al.. (2022). Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clinical Cancer Research. 28(19). 4203–4211. 17 indexed citations

Hengeveld, Paul J., Frédéric Davi, François G. Kavelaars, et al.. (2022). Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL. Blood. 141(5). 519–528. 12 indexed citations

Reinartz, Sebastian, Johannes Bloehdorn, Stephan Stilgenbauer, et al.. (2022). The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. Leukemia. 36(7). 1794–1805. 2 indexed citations

10.

Davids, Matthew S., Kirsten Fischer, Sandra Robrecht, et al.. (2021). ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 2634–2634. 8 indexed citations

11.

Bloehdorn, Johannes, Julia Krzykalla, Karlheinz Holzmann, et al.. (2021). Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. Haematologica. 107(3). 615–624. 2 indexed citations

12.

Al‐Sawaf, Othman, Sandra Robrecht, Jasmin Bahlo, et al.. (2020). Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 35(1). 169–176. 62 indexed citations

13.

Cramer, Paula, Julia von Tresckow, Anna‐Maria Fink, et al.. (2020). Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG). Blood. 136(Supplement 1). 21–23. 5 indexed citations

14.

Al‐Sawaf, Othman, Anna‐Maria Fink, Sandra Robrecht, et al.. (2019). Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial. Blood. 134(Supplement_1). 4315–4315. 8 indexed citations

15.

Al‐Sawaf, Othman, Alexandra Bazeos, Sandra Robrecht, et al.. (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology. 94(9). 1002–1006. 5 indexed citations

16.

Agathangelidis, Andreas, Christof Schneider, Jasmin Bahlo, et al.. (2019). Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 105(11). 2598–2607. 41 indexed citations

17.

Tausch, Eugen, Jasmin Bahlo, Sandra Robrecht, et al.. (2019). GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. Hematological Oncology. 37(S2). 84–86. 2 indexed citations

18.

Klymenko, Tetyana, Johannes Bloehdorn, Jasmin Bahlo, et al.. (2017). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 32(2). 364–375. 22 indexed citations

19.

Scheffold, Annika, Billy Michael Chelliah Jebaraj, Johannes Bloehdorn, et al.. (2017). High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment. Blood. 130. 390–390.

20.

Al‐Sawaf, Othman, Sandra Robrecht, Jasmin Bahlo, et al.. (2016). Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). Blood. 128(22). 4394–4394. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact